Prosensa Announces Extraordinary Shareholders Meeting to Appoint Dr. Georges Gemayel

Leiden, The Netherlands, Dec. 10, 2013 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the Dutch bio­phar­ma­ceu­ti­cal com­pa­ny focus­ing on rare dis­eases with a high unmet med­ical need, today announced that an Extraordinary General Meeting of Shareholders will be held on January 23rd, 2014 at 14:00 hrs. CET at the offices of Prosensa Holding N.V., J.H. Oortweg 21, 2333 CH Leiden, The Netherlands.
The pur­pose of the meet­ing is to appoint Dr. Georges Gemayel, PhD as a new Supervisory Board mem­ber.
Dr. Georges Gemayel cur­rent­ly serves on sev­er­al boards, includ­ing those of NPS Pharmaceuticals, Orphazyme, Vascular Magnetics and EpiTherapeutics. Previous board mem­ber­ships include Executive Chairman of the Board at FoldRx, a neu­rode­gen­er­a­tive dis­ease com­pa­ny that is now a whol­ly owned sub­sidiary of Pfizer and a board direc­tor at Adolor Corporation, which has since been acquired by Cubist Pharmaceuticals. Dr. Georges Gemayel’s oper­a­tional expe­ri­ence is exten­sive, hav­ing served as President & CEO of Waltham based Altus Pharmaceuticals and most notably as Executive Vice President of Genzyme Corporation from 2003 to 2008, among oth­ers.
“Georges will bring unpar­al­leled indus­try expe­ri­ence in the rare dis­ease space and strate­gic cor­po­rate lead­er­ship to our board at a piv­otal time for the com­pa­ny,” said David Mott, Chairman of the Supervisory Board of Prosensa.
Hans Schikan, Chief Executive Officer of Prosensa, added, “We wel­come Georges as an instru­men­tal addi­tion to our Supervisory Board. Georges’ exper­tise in rare dis­eases will be of tremen­dous val­ue in build­ing our com­pa­ny and devel­op­ing ther­a­pies for rare dis­eases with a high unmet med­ical need. His unique expe­ri­ence gleaned from his lead­er­ship at Genzyme will be invalu­able as we con­tin­ue to devel­op our pipeline of DMD can­di­dates.”
Dr. Georges Gemayel also added, “Prosensa has estab­lished a world-class team with excep­tion­al lead­er­ship and I am pleased to have the oppor­tu­ni­ty to con­tribute to the company’s growth in a mean­ing­ful way. It will be an hon­or to become part of a patient-cen­tric rare dis­ease orga­ni­za­tion which has been a pio­neer in the jour­ney of help­ing boys with Duchenne mus­cu­lar dys­tro­phy and their fam­i­lies.”
The notice and agen­da of the Extraordinary General Meeting are avail­able on the “Investors & Media” sec­tion of Prosensa’s web­site at www.prosensa.com. The notice of the Extraordinary General Meeting (which has been filed with the SEC on a Form 6-K) is also avail­able on the SEC’s web­site at www.sec.gov.

Leave a Reply

Your email address will not be published. Required fields are marked *